$ALC

Alcon terminates $14/share LENSAR merger after FTC regulatory delays. LENSAR stock crashes 25.44% to 52-week low of $7.65, destroying shareholder value.

DallasCISO honored seven security leaders at its 2026 ORBIE Awards ceremony, recognizing CISOs from major companies for their cybersecurity leadership and organizational transformation efforts.

Alcon's acquisition of LENSAR receives FTC Second Request, extending review. Companies expect deal to close in first half 2026 pending regulatory approval.

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.

Staar Surgical wins FDA approval to expand implantable lens eligibility to patients aged 21-60, up from 21-45, potentially reaching 8 million additional U.S. candidates.